CONGRESKALENDER

The Dutch UEGW Days: van UEGW naar IBD

10 oktober 2022


Voorwoord

Sprekers

Onder leiding van:

Marjolijn Duijvestein, MDL-arts
Radboudumc, Nijmegen

Maurice Lutgens, MDL-arts
ETZ, Tilburg

Programma

Maandag 10 oktober
10:00 - 10:15 Ontvangst en registratie
10:25 - 10:30 Opening door de voorzitters, voorstellen deelnemers, verwachtingen en doelstellingen
10:30 - 12:00 Blok 1 o.l.v. moderator
10:30 - 11:00 IBD biological therapie: huidige stand van zaken (M.Lutgens)
11:00 - 12:00 Programma UEG onderwerp (gezamenlijk live)
                         Treatment strategies in IBD
  • Clinical outcomes of increased versus conventional adalimumab dose intervals in patients with crohn’s disease in stable remission: the randomised controlled ladi trial
  • Treat-to-target maintenance efficacy and pharmacokinetics of ustekinumab dosing regimen up to week 48 in the stardust trial
  • The effect of guselkumab induction therapy in patients with moderately to severely active ulcerative colitis: quasar phase 2b induction results at week 12 by prior inadequate response or intolerance to advanced therapy
  • A cluster-randomised controlled trial of an enhanced treatment algorithm for the management of crohn’s disease: react-2
12:05 - 14:00 Netwerklunch en inchecken
14:00 - 17:30 Blok 2 o.l.v. moderator
14:00 - 15:00 Clinical trials in Crohn’s disease (gezamenlijk live)
 
  • Etrolizumab as induction and maintenance therapy in patients with moderately to severely active crohn’s disease: results from the phase 3 bergamot study
  • 52-weeks risankizumab subcutaneous maintenance dosing is efficacious and well tolerated in patients with moderate to severe crohn’s disease who had delayed response to 12-weeks iv risankizumab induction
  • Clinical and endoscopic improvements with risankizumab induction and maintenance dosing versus placebo are observed irrespective of number of prior failed biologics
  • Efficacy and safety of upadacitinib induction therapy in patients with moderately to severely active crohn’s disease: results from a randomized phase 3 u-excel study
  • Higher endoscopic and clinical remission rates with vedolizumab in early than in late crohn’s disease: results from the love-cd study (low countries vedolizumab in cd study)
15:00 - 15:30 Nabespreken Clinical trials in Crohn’s Disease
15:30 - 16:30 Real world evidence of tofacinitib in ulcerative colitis: short and long-term effectiveness, safety and impact of extraintestinal manifestations and immunomediated diseases
Third-line therapy in refractory ulcerative colitis: a comparison between tofacitinib and ustekinumab
16:30 - 17:30 Clinical trials in Ulcerative colitis
 
  • Etrasimod 2mg once daily as treatment for moderately to severely active ulcerative colitis: results from the phase 3 elevate uc 52 and elevate uc 12 trials
  • Induction combination therapy with guselkumab and golimumab followed by guselkumab monotherapy maintenance: results of the phase 2a, randomized, double-blind, proof-of-concept vega study
  • A phase 2 randomized, double-blind, placebo-controlled, multi-center study to evaluate the safety and efficacy of the oral, gut-restricted α4β7 integrin peptide antagonist pn-943 in patients with moderate to severe ulcerative colitis: results from the ideal study
  • Early symptom control with mirikizumab in patients with moderately to severely active ulcerative colitis in the lucent-1 induction trial
  • Oral ritlecitinib and brepocitinib in patients with moderate to severe active ulcerative colitis: chronic therapy data from the vibrato umbrella study
17:30 - 18:00 Recap dag 1 Q&A
19:00 - 21:00 Diner met kennisquiz o.l.v. moderatoren
   
Dinsdag 11 oktober
08:00 - 09:30 Uitchecken en ontbijt
09:30 - 10:30  Blok 3 o.l.v. moderator
 
  • IL-23p19 inhibitors
    • Matthieu Allez (France)
  • Anti-TNF's: Still the best option in Crohn's disease
    • Joana Torres (Portugal)
  • Small molecules for Crohn's disease
    • Silvio Danese (Italy)
10:30 - 11:00 Pauze
11:00 - 12:00 Blok 4 o.l.v. moderator (Gezamenlijk Live)
  Abstract-based Session
A1
Tuesday, October 11, 11:00 - 12:00
Clinical trials in ulcerative colitis II

op195 efficacy and safety of mirikizumab as maintenance therapy in patients with moderately to severely active ulcerative colitis: results from the phase 3 lucent-2 study
  • Geert D’Haens (Netherlands)
11:00 - 11:12 12 min
incl. 5 min discussion
op196 extended therapy with ozanimod for delayed responders to ozanimod in moderately to severely active ulcerative colitis: data from the true north open-label extension study
  • Remo Panaccione (Canada)
11:12 - 11:24 12 min
incl. 5 min discussion
op197 benefits of high versus low dose upadacitinib as maintenance treatment in ulcerative colitis patients who were responders to 8-week induction with upadacitinib: results from the u-achieve phase 3 maintenance trial
  • Brian Feagan (Canada)
11:24 - 11:36 12 min
incl. 5 min discussion
op198 efficacy of deucravacitinib, an oral, selective, tyrosine kinase 2 inhibitor, in patients with moderately to severely active ulcerative colitis and prior exposure to biologic therapy: subanalysis from the phase 2 lattice-uc study
  • Stefan Schreiber (Germany)
11:36 - 11:48 12 min
incl. 5 min discussion
op199 efficacy of upadacitinib dose escalation in a phase 3 long-term extension ulcerative colitis study
  • Remo Panaccione (Canada)
  OF
Moderated poster session: PROMS in IBD
12:00 - 13:00 Lunch
13:30 - 16:00 Blok 5 o.l.v. moderator
13:00 - 14:00 Therapy updates in UC
  • Janus Kinase inhibition: Class(y) effects or unique drugs?
    • Laurent Peyrin-Biroulet (France)
  • Blockade of cellular traficking: Anti-integrins and beyond?
    • Tim Raine (United Kingdom)
  • Anti-TNF-still the best option in ulcerative colitis?
    • Maria T. Abreu (United States)
14:00 - 15:00 (Gezamenlijk Live)
  Moderated poster session: response prediction in IBD
OF
Tuesday, October 11, 14:00 - 15:00
New insights in IBD IBD and cell migration: There is more to it
  • Sebastian Zundler (Germany)
14:00 - 14:20 20 min
incl. 10 min discussion
Modulation of S1P receptors: Towards the real mechanism
  • Bram Verstockt (Belgium)
14:20 - 14:40 20 min
incl. 10 min discussion
Somatic mutations: Impact on IBD
  • Sigurgeir Olafsson (United Kingdom)
   
  OF dus
Om 14:20 in andere sessie: Nutritional challenges in inflammatory bowel disease
  • Kevin Whelan (United Kingdom)
En om 14:30 nog twee nederlandse abstracts
UEG 2022 - Programme
15:00 - 15:30 Highlights nabespreken
15:30 Recap dag 2 Q&A en afsluiting The Dutch UEGW Days- Van UEGW naar IBD
   
   

Accreditatie

Locatie & Route

Boutique hotel Flora Batava,
Adres:
 		 Rijksstraatweg 6
3631 AC Nieuwersluis

 

Inschrijven